Curtain Raiser Release



2017 American Headache Society Annual Scientific Meeting Highlights Advances in Migraine Treatment and Research

MOUNT ROYAL, N.J., May 18, 2017 /PRNewswire/ — Leading clinical researchers on headache disorders, particularly migraine, cluster headache and post-traumatic headache, will present the latest data on new therapies at the American Headache Society (AHS)’s 59th Annual Scientific Meeting. The AHS accepted more than 220 scientific abstracts, which include the latest studies that will spotlight advances in research in multiple categories, such as pharmacological and non-pharmacological treatments, and disease epidemiology. The AHS Annual Scientific Meeting brings together more than 1,000 migraine and headache specialists from around the world. This year’s convention takes place June 8 – 11, 2017 in Boston, Massachusetts.

Migraine is the leading cause of disability worldwide due to a neurological disease that impacts more than 36 million men, women and children in the United States. For more than 90% of those affected, it interferes with education, career and social activities.

“The studies being presented at the 59th AHS Annual Scientific Meeting show that we’re making real progress toward better treatment options for individuals with migraine and a deeper understanding of how the disease affects patient populations,” said Peter Goadsby, MD, PhD, FAHS, AHS Scientific Program Committee Chair, Professor of Neurology, King’s College London and University of California, San Francisco, and Director, NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London. “We’re very excited to be presenting such a broad spectrum of data that sheds light on such an incredible medical need, while also bringing hope to individuals living with a disease that often impacts them in the prime of their lives.”

Dr. Goadsby will be highlighting the most important and groundbreaking data during a webcast on June 8, 2017 at 9:00 am ET. Additional information and registration details can be found here:

Following is a select list of abstracts for the platform presentations (note that presenters are subject to change):

Friday, June 9, 2017

  • 12:25 pm – 12:35 pm
    Pediatric Patient and Parent Goals and Preferences for Preventive Headache Treatment
    Christina Szperka, MD (ID number: OR05)
  • 12:35 pm – 12:45 pm
    Premonitory Symptoms in Pediatric Migraine: A Prospective Study
    Howard Jacobs, MD (ID number: OR06)

Saturday, June 10, 2017

  • 8:00 am – 8:10 am
    Multi-Sensory Neuromodulation of Migraine: A Role for Vestibular Stimulation
    Carey Balaban, PhD (ID number: IOR01)
  • 8:10 am – 8:20 am
    A Multicenter, Prospective, Single Arm, Open Label, Post-Market, Observational Study to Evaluate the Use of sTMS in Reduction of Migraine Headache (ESPOUSE Study)
    Amaal Starling, MD (ID number: IOR02)
  • 8:20 am – 8:30 am
    Non-invasive Vagus Nerve Stimulation for the Acute Treatment of Episodic and Chronic Cluster Headache: Findings from the Randomized, Double-blind, Sham-Controlled ACT2 Study
    Eric J. Liebler (ID number: IOR03)
  • 8:30 am – 8:40 am
    Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Dan Mikol, MD, PhD (ID number: IOR04)
  • 8:40 am – 8:50 am
    Fremanezumab (formerly TEV-48125) Reduces Headache Pain Within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study
    Ernesto Aycardi, MD (ID number: IOR05)
  • 8:50 am – 9:00 am
    Randomized, Double-Blind, Placebo-Controlled Trial of ALD403 (eptinezumab), an Anti-CGRP Monoclonal Antibody for the Prevention of Chronic Migraine
    Jeffrey T. Smith, MD (ID number: IOR06)
  • 9:00 am – 9:10 am
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
    Stewart J. Tepper, MD, FAHS (ID number: IOR07)
  • 9:20 am – 9:30 am
    Efficacy of Zolmitriptan Nasal Spray for the Treatment of Acute Migraine in Adolescents: Subgroup Analysis by Age
    Paul Winner, DO, FAHS (ID number: IOR09)
  • 10:30 am – 10:40 am
    A Randomized Study of Prochlorperazine versus Hydromorphone for Acute Migraine
    Benjamin W. Friedman, MD, MS, FAHS (ID number: OR09)

Following is a select list of abstracts that will be presented as posters:

Friday, June 9, 2017

  • ALD403 (eptinezumab) Elicits Meaningful Reductions in Migraine Activity 24 Hours After a SingleIntravenous Administration
    Jeffrey Smith, MD, FCRP (ID number: PF76)
  • Galcanezumab Administration Was Not Associated with Increase in Blood Pressure in Patients with Osteoarthritis
    Sheena Aurora, MD (ID number: PF08)
  • Mapping Pain in Pediatric Migraine
    Allison Ludwick, MSc (ID number: PF50)

Saturday, June 10, 2017

  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial
    David W. Dodick, MD, FAHS (ID number: PS21)
  • Efficacy of Erenumab for the Treatment of Patients with Chronic Migraine in Presence of Medication Overuse
    Stewart Tepper, MD (ID number: PS32)
  • Early Onset of Efficacy in a Phase 2 Clinical Trial of Erenumab in Patients with Chronic Migraine
    Stewart Tepper, MD (ID number: PS24)
  • Chronic Migraine Treatment with Erenumab: Responder Rates
    Jan Brandes, MD, FAAN (ID number: PS33)
  • Fremanezumab Increases the Maximum Number of Consecutive Headache-Free Days for Patients with High Frequency Episodic Migraine
    Robert Noble, PhD (ID number: PS10)
  • Fremanezumab (formerly TEV-48125) Decreases Migraine Symptoms Such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study
    Ernesto Aycardi, MD (ID number: PS09)
  • Sustained Migraine and Headache Day Improvement with Fremanezumab (TEV-48125)
    Rashmi Halker, MD (ID number: PS11)
  • Headache Severity in Veterans Deployed to Afghanistan or Iraq Wars at 2-11 Years After Traumatic Brain Injury
    James Couch, MD, PhD (ID number: PS59)
  • Safety and Tolerability of Galcanezumab in a Phase 2 Migraine Prevention Study
    Tina Oakes, PhD (ID number: PS19)
  • Hepatic Safety of Galcanezumab in Patients with Migraine: Results of Three Phase 2 Double-Blind Placebo-Controlled Trials
    Vladimir Skljarevski, MD (ID number: PS05)

Online Annual Meeting Press Room
Visit for press guidelines and releases, as well as information on press room, press passes, embargo policies, and photo/video policy.

About Peter Goadsby, MD, PhD, FAHS
Dr. Peter Goadsby is the AHS Scientific Program Committee Chair; Professor of Neurology, King’s College London and University of California, San Francisco; and Director, NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, London. His major research interests are in the basic mechanisms of primary headache disorders, such as migraine and cluster headache, in both experimental and clinical settings, and translating these insights into their better management.

About Migraine
Migraine is a major disabling neurological disease that affects more than 36 million men, women and children in the United States. The disease impacts one in four households, one in five women, one in 16 men and one in 11 children in the United States. Globally, migraine is the sixth highest cause of years of life lost due to disability. Individuals who experience migraine have symptoms that include nausea, sensitivity to light and/or odors, skin sensitivity, fatigue, mood change, dizziness, difficulty concentrating, neck pain and changes in vision, including seeing spots, stars, lines, flashing lights and zigzag lines. The risk of other serious diseases is significantly higher in those with migraine, including stroke, epilepsy, depression, anxiety and chronic pain. Despite this, only one of every three people talk with a doctor about their migraine attacks and of those, only half get the right diagnosis. There is also a massive shortage of specialists focusing on migraine, with one specialist for every 65,000 individuals living with migraine, which worsens the problem.

About the American Headache Society
The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society’s objectives are to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals and the public and encouraging scientific research are the primary functions of this organization. AHS activities include an annual scientific meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, and publication of the journal Headache. More information can be found at In 2010 AHS founded the American Migraine Foundation (AMF) to provide access to information and resources for individuals living with migraine, as well as their loved ones. AMF is a non-profit organization dedicated to the advancement of research and awareness surrounding migraine. Patients can learn more, find help and get connected by visiting

CONTACT: Amra Maynard,, +1 212 845 5625 and +1 917 302 2702

Back to Press Releases